172 related articles for article (PubMed ID: 26728163)
1. Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model.
De Bruycker S; Vangestel C; Van den Wyngaert T; Wyffels L; Wouters A; Pauwels P; Staelens S; Stroobants S
Mol Imaging Biol; 2016 Aug; 18(4):606-16. PubMed ID: 26728163
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of [
Jiang H; Zhang R; Jiang H; Zhang M; Guo W; Feng G; Pan W; Xu H; Wang S
Nucl Med Biol; 2019; 72-73():36-44. PubMed ID: 31330410
[TBL] [Abstract][Full Text] [Related]
3.
Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H
Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H
Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468
[TBL] [Abstract][Full Text] [Related]
5. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
[TBL] [Abstract][Full Text] [Related]
6.
Zhang MY; Zhang RJ; Jiang HJ; Jiang H; Xu HL; Pan WB; Wang YQ; Li X
Hepatobiliary Pancreat Dis Int; 2019 Apr; 18(2):164-172. PubMed ID: 30850340
[TBL] [Abstract][Full Text] [Related]
7. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668
[TBL] [Abstract][Full Text] [Related]
8. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
Cheng J; Lei L; Xu J; Sun Y; Zhang Y; Wang X; Pan L; Shao Z; Zhang Y; Liu G
J Nucl Med; 2013 Mar; 54(3):333-40. PubMed ID: 23401605
[TBL] [Abstract][Full Text] [Related]
9. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer.
Dong S; Liang S; Cheng Z; Zhang X; Luo L; Li L; Zhang W; Li S; Xu Q; Zhong M; Zhu J; Zhang G; Hu S
J Exp Clin Cancer Res; 2022 Jan; 41(1):15. PubMed ID: 34998404
[TBL] [Abstract][Full Text] [Related]
10. In vivo evaluation of the effects of simultaneous inhibition of GLUT-1 and HIF-1α by antisense oligodeoxynucleotides on the radiosensitivity of laryngeal carcinoma using micro 18F-FDG PET/CT.
Shen LF; Zhao X; Zhou SH; Lu ZJ; Zhao K; Fan J; Zhou ML
Oncotarget; 2017 May; 8(21):34709-34726. PubMed ID: 28410229
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive evaluation of
Zhang M; Jiang H; Zhang R; Xu H; Jiang H; Pan W; Li X; Wang Y; Wang S
Sci Rep; 2018 Dec; 8(1):17832. PubMed ID: 30546057
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of [
Rapic S; Vangestel C; Elvas F; Verhaeghe J; den Wyngaert TV; Wyffels L; Pauwels P; Staelens S; Stroobants S
Mol Imaging Biol; 2017 Aug; 19(4):560-569. PubMed ID: 28050749
[TBL] [Abstract][Full Text] [Related]
13.
Grkovski M; Emmas SA; Carlin SD
J Nucl Med; 2017 Oct; 58(10):1567-1573. PubMed ID: 28360207
[TBL] [Abstract][Full Text] [Related]
14. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Thézé B; Bernards N; Beynel A; Bouet S; Kuhnast B; Buvat I; Tavitian B; Boisgard R
BMC Cancer; 2015 Jul; 15():534. PubMed ID: 26198000
[TBL] [Abstract][Full Text] [Related]
15. HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy.
Nakamura J; Kitajima Y; Kai K; Hashiguchi K; Hiraki M; Noshiro H; Miyazaki K
Int J Cancer; 2010 Sep; 127(5):1158-71. PubMed ID: 20020496
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic activation of tumor hypoxia: a means to increase tumor 2-deoxy-2-[18F]fluoro-D-glucose uptake?
Mees G; Dierckx R; Vangestel C; Laukens D; Van Damme N; Van de Wiele C
Mol Imaging; 2013; 12(1):49-58. PubMed ID: 23348791
[TBL] [Abstract][Full Text] [Related]
17. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
Troost EG; Laverman P; Kaanders JH; Philippens M; Lok J; Oyen WJ; van der Kogel AJ; Boerman OC; Bussink J
Radiother Oncol; 2006 Aug; 80(2):157-64. PubMed ID: 16905213
[TBL] [Abstract][Full Text] [Related]
18. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
19. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H
Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694
[TBL] [Abstract][Full Text] [Related]
20. Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas.
Kawai N; Lin W; Cao WD; Ogawa D; Miyake K; Haba R; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1870-8. PubMed ID: 24781871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
